Anti-Cancer Agents in Medicinal Chemistry- Anti-Cancer Agents)

Editorial [ Hot Topic:Emerging Anticancer Effects of Antiresorptive Therapies (Guest Editor: Vera Hirsh)]
pp. 94-94(1)
Author: Hirsh, Vera

The Chemistry of Bisphosphonates: From Antiscaling Agents to Clinical Therapeutics
pp. 95-101(7)
Authors: Widler, Leo; Jahnke, Wolfgang; R. Green, Jonathan

Potential Anticancer Properties of Bisphosphonates: Insights From Preclinical Studies
pp. 102-113(12)
Author: Clezardin, Philippe

Anticancer Activity of Bisphosphonates in Breast Cancer
pp. 114-122(9)
Author: Gnant, Michael

Bisphosphonate Anticancer Activity in Multiple Myeloma
pp. 123-128(6)
Author: Terpos, Evangelos

Bisphosphonate Anticancer Activity in Prostate Cancer and Other Genitourinary Cancers
pp. 129-136(8)
Authors: Saad, Fred; Mulders, Peter

Bisphosphonates in Lung Cancer: Can They Provide Benefits Beyond Prevention of Skeletal Morbidity?
pp. 137-143(7)
Author: Hirsh, Vera

Bisphosphonates and Breast Cancer Prevention
pp. 144-150(7)
Authors: T. Chlebowski, Rowan; Col, Nananda

Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance
pp. 151-162(12)
Authors: S. Gayle, Sylvia; L.M. Arnold, Samuel; M. O'Regan, Ruth; Nahta, Rita

Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
pp. 163-171(9)
Author: Yokota, Tomoya

Procathepsin D as a Tumor Marker, Anti-Cancer Drug or Screening Agent
pp. 172-175(4)
Authors: Vetvicka, Vaclav; Fusek, Martin